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Abstract Activation of CD1d-restricted invariant NKT (iNKT) cells with the glycolipid
α-galactosylceramide (α-GalCer) confers protection against disease in murine models, however,
clinical trials in humans have had limited impact. We synthesized a novel thioglycoside analogue of
α-GalCer, denotedα-S-GalCer, and tested its efficacy for stimulating human iNKT cells in vitro.α-S-
GalCer stimulated cytokine release by iNKT cells in a CD1d-dependent manner and primed CD1d+
target cells for lysis. α-S-GalCer-stimulated iNKT cells induced maturation of monocyte-derived
dendritic cells into antigen-presenting cells that released IL-12 and small amounts of IL-10. The
nature and potency of α-S-GalCer and α-GalCer in human iNKT cell activation were similar.
However, in contrast to α-GalCer, α-S-GalCer did not activate murine iNKT cells in vivo. Because of
its enhanced stability in biological systems, α-S-GalCer may be superior to α-GalCer as a parent
compound for developing adjuvant therapies for humans.
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Figure 1 Molecular structures of α-GalCer and the thioglyco-
side analogue (α-S-GalCer) used in the present investigation.
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Invariant natural killer T (iNKT) cells are unconventional
regulatory and effector T cells that recognize glycolipid
antigens presented by the major histocompatibility complex
(MHC) class I-like molecule CD1d [1,2]. They can be activated
by a number of endogenous and bacterial glycosphingolipids
[3,4], but the xenogeneic glycolipid, α-galactosylceramide
(α-GalCer), a potent agonist for murine and human iNKT cells
[5] has been used as the prototype antigen for most studies
on iNKT cells. Upon in vitro activation with α-GalCer, iNKT
cells kill a range of tumor cell lines [6], rapidly release
cytokines [2,7,8], promote maturation of dendritic cells (DC)
into antigen-presenting cells (APC) [9–12] and promote
maturation of B cells into antibody-secreting plasma cells
[13,14]. Studies in murine models of disease have demon-
strated critical roles for iNKT cells in the prevention and
reversal of tumor growth, prevention of autoimmune
disease, and immunity against a diversity of microbial
pathogens [15–18]. Numerical and functional deficiencies
of iNKT cells have been reported in humans with various
diseases [19,20] but clinical trials involving α-GalCer
stimulation of iNKT cells have yielded disappointing results
[21,22].
A notable feature of iNKT cells is their ability to rapidly
release cytokines that exert major effects on early and
delayed adaptive immunity against tumors and infectious
pathogens [2,7,8]. α-GalCer stimulation of murine and
human iNKT cells results in the simultaneous production of
the Th1 cytokine interferon-γ (IFN-γ) and the Th2 cytokines
IL-4 and IL-13 [7,8]. Th1 cytokines are thought to be critical
for the antitumor effects of α-GalCer, while the Th2
cytokines can attenuate antitumor immunity and autoim-
mune disease pathology [17,23,24]. Therefore, the efficacy
of α-GalCer may be limited by reciprocal inhibition exhibited
by Th1 and Th2 cytokines and this may be reflected in the low
efficacy of α-GalCer for the treatment of solid tumors in a
phase I study [25]. Hence, a number of α-GalCer derivatives
and analogues have been synthesized to develop compounds
which can selectively induce particular responses in iNKT
cells. Modifications to the galactose residue revealed that
the α-anomeric configuration is a key pharmacophoric
element of α-GalCer [26,27]. Modifications to the acyl
chains, including shortening [28–30] and the introduction
of double bonds [31] resulted in iNKT cell ligands that
preferentially stimulated Th2 cytokine secretion, while the
addition of aromatic groups resulted in Th1-inducing ligands
[32,33]. Substitution of the O-glycosidic linkage in α-GalCer
with a C-glycosidic linkage resulted in a Th1-inducing
compound with 100-fold greater antimetastatic activity in
mice [34]. Silk and co-workers [35] identified threitol
ceramide as a weak iNKT cell agonist, which led to the
advantage for some applications of less consequent killing of
CD1d+ APC by iNKT cells and lowered anergic effects on
repeated exposure.
We recently synthesized a thioglycoside analogue of
α-GalCer (α-S-GalCer; Fig. 1) using a novel approach that
resulted in the galactosyl thiol being produced exclusively as
α-anomers [36]. Here we show that this α-S-GalCer com-
pound binds CD1d and stimulates cytotoxicity and cytokine
secretion by human peripheral blood iNKT cell lines and
renders them capable of inducing maturation of DCs intoAPCs. This is the first demonstration of a thioglycoside
analogue of α-GalCer that activates iNKT cells. Its increased
stability in biological systems and enhanced flexibility around
the anomeric linkage places α-S-GalCer and its substituted
derivatives as a potentially superior family of ligands,
compared to α-GalCer, for therapeutic activation of human
iNKT cells.2. Materials and methods
2.1. Antibodies and flow cytometry
Fluorochrome-conjugated monoclonal antibodies (mAb) spe-
cific for human CCR7, CD1d, CD3, CD4, CD8, CD11c, CD14,
CD40, CD54, CD80, CD83, CD86, CD107a, HLA-DR, the Vα24
and Vβ11 chains that form the T cell receptor (TCR) present
on iNKT cells, the complementarity-determining region-3 of
the invariant Vα24Jα18 TCR chain (6B11) and isotype control
mAbs were obtained from BD Biosciences (Oxford, UK),
Immunotools (Friesoythe, Germany), R&D Systems (Abing-
don, UK), eBioscience (Hatfield, UK) or Coulter Immunotech
(Galway, Ireland). Following staining, cells were analyzed
using a FACSCalibur flow cytometer with CellQuest software
(BD Biosciences).2.2. Generation of iNKT cell lines
Peripheral blood mononuclear cells (PBMC) were prepared
from healthy blood donors by standard density gradient
centrifugation over Lymphoprep (Nycomed Pharma, Oslo,
Norway). iNKT cells were sorted from PBMC by staining with a
phycoerythrin (PE)-conjugated anti-iNKT cell mAb (clone
6B11) followed by positive selection of the PE-positive cells
by magnetic bead separation using anti-PE magnetic beads
(Miltenyi Biotec, Bergisch-Gladbach, Germany). In some
cases iNKT cells were enriched by flow cytometric sorting
of 6B11-positive cells using a MoFlo™ XDP Cell Sorter
(Beckman Coulter).
Sorted iNKT cells were expanded in vitro using two
different methods that were developed in our laboratory and
yielded sufficient numbers of iNKT cells for functional
studies. Method 1 involved culturing 1,000 iNKT cells in
complete RPMI medium (RPMI 1640 containing 0.05 mM
198 A.E. Hogan et al.L-glutamine, 0.05 mM β-mercaptoethanol, 10% HyClone fetal
calf serum or FCS, 1% penicillin-streptomycin, 1% fungizone
and 25 mM HEPES; Gibco-BRL, Paisley, UK and Thermo-
Scientific, Logan, UT) and stimulating them with 1 μg/ml
phytohaemagglutinin (PHA-P; Sigma-Aldrich, Dublin, Ireland)
and 250 U/ml IL-2 (R&D Systems, Abingdon, UK) in the
presence of an excess (2×105) of irradiated allogeneic PBMC
prepared from two donors. After 24 h and again after 48 h,
mediumwas replaced withmedium containing 250 U/ml IL-2.
Cells were restimulated as above every 28 days.
Method 2 for expanding iNKT cells involved culturing the
cells in complete RPMI medium and giving them a single
stimulation with 1 μg/ml plate-bound anti-CD3 mAb (OKT3 or
HIT3A; BDBiosciences) in the absence of irradiated feeder cells.
After 24 h, themediumwas supplementedwith 100 U/ml of IL-2
and cells were cultured for 2 weeks, after which spent medium
was replacedwith complete RPMI containing 50 U/ml IL-2. Cells
were split into multiple wells when confluency exceeded 50%.
Purity and phenotype of iNKT cell lines were assessed by flow
cytometry after staining the cells with mAbs specific for CD3,
6B11, Vα24, Vβ11, CD4 and CD8.
2.3. Glycolipids
α-GalCer (KRN7000) was purchased from Funakoshi Co. Ltd,
(Tokyo, Japan). The thioglycoside analogue of α-GalCer
(α-S-GalCer) was synthesized as described previously [36].
Briefly, α-galactosyl thiol was prepared from the benzylated
1,6-anhydrogalactose in very high yield, and then coupled with
the electrophilic sphingoid iodide under phase transfer condi-
tions, to give the α-linked product. Notably, the α-galactosyl
thiol was produced exclusively as α-anomer, which made
the purification simple and straightforward. Eventually the
α-S-GalCer was synthesized in a linear sequence of 14 steps
with 3% overall yield.
Glycolipid stocks were prepared by suspending solid
α-GalCer or α-S-GalCer in dimethylsulphoxide (DMSO) to a
final concentrations of 1 mM by heating for 2 min at 80 °C
followed by sonication for 5 min and vortexing for 1 min.
These stocks were stored at −20 °C. Working stocks
containing 100 μM glycolipids were made by further
dilution in phosphate buffer saline by heating for 2 min
at 80 °C followed by sonication for 10 min and vortexing
for 1 min. These stocks were stored at 4 °C before adding
to cell cultures.
2.4. Analysis of cytokine secretion by iNKT cells
iNKT cells were stimulated in vitro using mock-transfected or
CD1d-transfected HeLa [33] or C1R cells [7] pulsed with
glycolipid or vehicle. The HeLa and C1R transfectant cells
were a kind gift from Steven Porcelli (Albert Einstein College
of Medicine, New York, USA) and were maintained at a
density of 0.5×106 cells/ml in complete DMEM and RPMI
medium, respectively, at 37 °C with 5% CO2. 2×105 HeLa or
C1R mock- or CD1d-transfectant cells were cultured in
round-bottomed 96-well tissue culture plates and pulsed
with various amounts of glycolipid antigen or vehicle control
for 2–24 h before adding an equal number of iNKT cells,
which were expanded as described above but allowed to rest
by culturing for 4 weeks in the absence of stimulation. After24–72 h, supernatants were assayed for granulocyte-mono-
cyte colony-stimulating factor (GM-CSF), IFN-γ, IL-4 or IL-13
by enzyme-linked immunosorbent assay (ELISA) using anti-
body pairs purchased from R&D Systems. In some cases,
blocking anti-CD1d (clone 42.1) mAb was added at a
concentration of 10 μg/ml to test for CD1d dependency.
2.5. Cytotoxicity assays
The capacity of α-GalCer and α-S-GalCer to prime CD1d+ C1R
cells for cytotoxicity by iNKT cells was tested using the flow
cytometry-based Total Cytotoxicity and Apoptosis Detection
Kit (Immunochemistry Technologies, Bloomington, MN, USA).
Briefly, target cells were incubated with a 1:250 dilution of
stock carboxyfluorescein succinimidyl ester (CFSE) at 37 °C
with 5% CO2 for 30 min. The reaction was quenched by adding
10 ml cold cRPMI. Target cells were pelleted at low speed
and incubated with expanded iNKT cells at ratios of 1:1, 10:1
and 20:1 for 4 h at 37 °C with 5% CO2. After incubation, cells
were harvested and incubated on ice. 7-aminoactinomycin D
(7-AAD; 1:10 dilution) was added immediately before
acquisition by flow cytometry. An electronic gate was used
to select the CFSE positive target cells. CFSE positive cells
which stained positive for 7-AAD are deemed to be recently
apoptosed cells. Cytolytic degranulation of iNKT cells
cultured with CD1d- and CD1d+ C1R cells, Jurkat and THP-1
target cells was examined by flow cytometric analysis of
CD107a expression by 6B11-positive effector cells. In these
experiments, iNKT cells and target cells were co-cultured for
4 h in the presence of anti-CD107a mAb and monensin
(25 μM; Sigma-Aldrich) was added after 1 h to prevent re-
internalisation of CD107a.
2.6. DC functional assays
Monocytes were enriched from PBMC isolated from buffy
coat packs by positive selection using CD14 Microbeads
(Miltenyi Biotec). CD14+ PBMC (containing N90% CD14+ cells)
were allowed to differentiate into immature DC by culturing
them at a density of 106 cells/ml using 3 ml/well of a 6-well
plate (Corning, Amsterdam, Netherlands) in complete RPMI
medium made with low-endotoxin FCS (Defined serum,
HyClone) containing 50 ng/ml GM-CSF and 70 ng/ml IL-4.
Cells were cultured for 6 days, replacing with fresh medium
containing cytokines on day 3. Cells in some wells were
cultured similarly but in the absence of cytokines, as
monocyte controls. On day 6, DC were removed from the
wells by aspiration using a wide-gauge Pasteur pipette
whereas monocytes were gently scraped from the wells
using a cell scraper (Sarstedt, Drinagh, Ireland). Cells were
washed with warm RPMI medium. Flow cytometry was used
to verify that differentiation into DC had taken place and
cells expressed HLA-DR and CD11c but not CD14.
DC were cultured at 0.2×106 cells/well in 96-well plates
and induced to mature by culturing them for 24 h in medium
alone or with lipopolysaccharide (LPS; 1 μg/ml; Alexis
Biochemicals, Exeter, UK), polyinosinic:polycytidylic acid
(poly I:C) double stranded RNA (75 μg/ml; Sigma-Aldrich), or
equal numbers of allogeneic iNKT cells in the absence or
presence of α-GalCer or α-S-GalCer. In some wells PBMC
expanded using Methods 1 or 2, as described above for
199Human invariant natural killer T cells with a thioglycoside analogueexpanding iNKT cells, were included as a non-iNKT cell
control. After 24 h, the cell supernatants were assayed for IL-
10 and IL-12p70 production by ELISA (R&D Systems) and DC
were examined for expression of CCR7, CD11c, CD40, CD54,
CD80, CD83, CD86 and HLA-DR using flow cytometry.
2.7. In vivo studies in mice
Female C57BL/6J mice (Harlan, UK) were injected intrave-
nously with 1 or 2 μg α-GalCer or α-S-GalCer prepared in PBS.
PBS-alone was also injected as a vehicle control. Blood was
removed and serum recovered 3 and 18 h after injection. The
levels of IFN-γ and IL-4 in serum were determined by ELISA
using reagents purchased from R&D Systems (Minneapolis,
MN, USA).
2.8. Statistical analyses
Statistical analysis was carried out using Prism GraphPad
Version 5.0. Differences between groups were assessed using
the Mann–Whitney U test or paired t test where appropriate.
p Values of b0.05 were considered significant.
3. Results
3.1. Generation of iNKT cell lines
iNKT cell lines were generated using Method 1 (PHA,
irradiated feeders and IL-2) or Method 2 (anti-CD3 mAb and
IL-2) and phenotypically examined by flow cytometry. iNKT
cell lines prepared using both methods yielded similar
numbers of cells and consisted of CD4+, CD8+ and CD4-CD8-
double negative iNKT cells (Fig. 2), indicating that all three
subsets could be expanded.
3.2. Human iNKT cells release Th1 and Th2
cytokines in response to α-S-GalCer presented
by CD1d
iNKT cells expanded using Method 1 (PHA, irradiated feeder
cells and IL-2) were co-cultured with equal numbers of mock-
transfected or CD1d transfected HeLa cells that were
unloaded or loaded with varying concentrations of α-GalCer
or α-S-GalCer. After 24 h, supernatants were harvested and
assayed for levels of cytokines secreted by ELISA. ResultsFigure 2 Purity and phenotype of iNKT cell lines. iNKT cells were s
and methods. Flow cytometry dot plots show expression of CD3 and th
CD4 and CD8 (right) by a representative iNKT cell line.from 5 experiments using three different iNKT cell lines
showed that iNKT cells responded to both glycolipids in the
presence of CD1d-transfected HeLa cells but not in the
presence of mock-transfected HeLa cells (Fig. 3A). Both
α-GalCer and α-S-GalCer induced the secretion of GM-CSF,
IFN-γ, IL-4 and IL-13 by iNKT cells in a dose-dependent
manner. The levels of each cytokine released in response to
the two glycolipids did not differ significantly, suggesting
that substituting the O-glycosidic linkage onα-GalCer with an
S-linkage does not skew the Th1/Th2 cytokine balance of
iNKT cells. Similar results were obtained using iNKT cells
expanded usingMethod 2 (anti-CD3mAb and IL-2) co-cultured
with mock-transfected and CD1d-transfected C1R cells
(Fig. 3B). Data from 6 experiments using six different iNKT
cell lines show that both α-GalCer and α-S-GalCer stimulated
IFN-γ and IL-4 production by iNKT cells and this was blocked
by preincubating the CD1d+ C1R cells with an anti-CD1d mAb.
Thus, α-S-GalCer stimulates human iNKT cells in a CD1d-
dependent manner inducing similar patterns of cytokine
secretion as the prototype glycolipid α-GalCer.3.3. α-S-GalCer primes CD1d-positive target cells
for lysis by iNKT cells
Expanded iNKT cells were co-cultured with mock-trans-
fected or CD1d-transfected C1R cells or the CD1d-positive
transformed cells lines Jurkat and THP-1 in the absence or
presence of 100 ng/ml α-GalCer or α-S-GalCer. After 4 h,
cytolytic degranulation of the iNKT cell effector cells was
measured by flow cytometric analysis of cell-surface CD107a
expression (Fig. 4A). Figure 4A and B shows that little or no
degranulation occurred in the absence of CD1d expression by
the target cells or addition of glycolipids. Both glycolipids
significantly primed CD1d+ target cells for degranulation by
iNKT cells with α-S-GalCer being significantly less potent
than the parent α-GalCer. Apoptosis of CFSE-labelled target
cells was also examined by culturing mock- or CD1d-
transfected C1R cells with iNKT cells at various effector/
target ratios in the absence or presence of 100 ng/ml α-
GalCer or α-S-GalCer. After 4 h, apoptotic CFSE-positive
cells were detected by flow cytometric analysis of 7-AAD
expression (Fig. 4C). Figure 4D shows that iNKT cells in the
absence of added antigen displayed weak cytotoxicity
against CD1d+ C1R target cells. Addition of either glycolipid
resulted in increased cytolytic activity. No cytotoxicity was
observed when mock-transfected C1R cells were used asorted from human blood and expanded as described in Materials
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Figure 3 Human iNKT cell recognize α-S-GalCer in a CD1d-dependent manner. A, iNKT cells were co-cultured with mock-
transfected or CD1d transfected HeLa cells unloaded or loaded with varying concentrations of either α-GalCer or α-S-GalCer and levels
of released GM-CSF, IFN-γ, IL-4 and IL-13 were examined 48 h later by ELISA. Results show mean and SD cytokine levels from 5
independent experiments using 3 different iNKT cell lines (one experiment using the mock-transfectant cell line). B, iNKT cells were
co-cultured with mock-transfected or CD1d-transfected C1R cells in the absence or presence of 100 ng/ml α-GalCer or α-S-GalCer,
with each treatment in the absence or presence of a blocking anti-CD1d mAb. Levels of released IFN-γ (left) were measured after 72 h
by ELISA. Levels of IL-4 (right) were measured after 24 h. The bar graphs display the mean levels of cytokine secretion from 6
independent experiments. *pb0.01; **pb001 compared to cytokine levels released by C1R-mock cells alone.
200 A.E. Hogan et al.targets in the absence or presence of either glycolipid (data
not shown). Thus, α-S-GalCer induces cytotoxicity by iNKT
cells against some tumor cells but with a stimulatory
capacity that may be less potent than α-GalCer.3.4. α-S-GalCer-stimulated iNKT cells induce
maturation of monocyte-derived DC
iNKT cells can induce maturation of immature DC into APCs
that are capable of activating naïve αβ T cells [9–12]. Wecompared the capacity of α-S-GalCer and α-GalCer in
combination with iNKT cells to induce DC expression of
MHC, costimulatory and adhesion molecules that are
associated with antigen presentation. The intensities of
mAb staining for each marker were determined by flow
cytometry (Fig. 5A) and the fold-increases in the average
mean MFI of marker expression over those of immature DC
were determined for 3 independent experiments. Immature
monocyte-derived DC incubated for 24 h with LPS or poly I:C
exhibited significant upregulation of CCR3, CD40, CD54,
CD86 and HLA-DR but not CD83 nor CD80 (Fig. 5B). Incubation
Figure 4 α-S-GalCer primes CD1d-positive target cells for lysis by iNKT cells. A, Flow cytometric dot plots showing cell surface
expression of CD107a by iNKT cells (6B11+) incubated alone or following culture for 4 h with CD1d-transfected C1R target cells
unloaded or loaded with 100 ng/ml α-GalCer or α-S-GalCer. B, Percentages of iNKT cells that expressed CD107a after culture with
mock- or CD1d-transfected C1R cells, Jurkat or THP-1 cells in the absence or presence of α-GalCer or α-S-GalCer. Results are means
(±SEM of experiments using 3 different iNKT cell lines. C, Flow cytometric dot plots showing expression of 7-aminoactinomycin D
(7-AAD) by CFSE-labeled CD1d-transfected C1R cells cultured alone or in the presence of iNKT cells at effector/target ratios of 10/
1 in the presence of 100 ng/ml α-GalCer or α-S-GalCer. D, Mean percentages of CFSE labeled CD1d transfected C1R target cells
that expressed 7-AAD after culturing with iNKT cells in the absence or presence of α-GalCer or α-S-GalCer. Results are means of 3
independent experiments with different iNKT cell lines. *pb0.005.
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glycolipid antigen also resulted in significant upregulation of
CD54 and CD86 expression and weak (non-significant)
upregulation of expression of the other markers that were
induced by LPS or poly I:C. Addition of α-GalCer or α-S-GalCer to the DC-iNKT cell co-cultures resulted in further
upregulation of CCR7, CD40, CD54, CD83, CD86 and HLA-DR
with both glycolipids having similar effects. As controls, non-
iNKT cells consisting of PBMC expanded using PHA and IL-2
were also co-cultured with the DC, but these cells did not
Figure 5 α-S-GalCer-stimulated iNKT cells induce maturation of monocyte-derived DC. Immature monocyte-derived DC were
incubated for 24 h in medium alone or with 1 μg/ml LPS, 75 μg/ml poly I:C double stranded RNA or equal numbers of iNKT cells in the
absence or presence of α-GalCer and α-S-GalCer. Non-iNKT cells consisted of PBMC expanded with PHA and IL-2 as a control cell
population. A, Representative flow cytometry histograms showing intensities of CCR7, CD40, CD54, CD80, CD83, CD86 and HLA-DR
expression by iDC cultured alone (filled histograms), cultured with iNKT in the presence of αGalCer (thin lines) or cultured with iNKT in
the presence of α-S-GalCer (bold lines). B, Bar charts showing the average mean fluorescence intensities (mfi) in 3 independent
experiments expressed as fold increases in mfi compared with the mfi of immature DC. *pb0.05 and **pb0.01 compared with the mfi
of immature DC; ns, not significant comparing the effects of α-GalCer and α-S-GalCer (shown by square brackets).
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Figure 6 α-S-GalCer stimulated iNKT cells induce IL-12, and to a lesser degree, IL-10 release by monocyte-derived dendritic cells
(DC). Immature DC were cultured in medium alone, with 1 μg/ml LPS, 100 ng/ml α-GalCer or α-S-GalCer, or co-cultured with iNKT
cells or non-iNKT cells in the absence or presence of α-GalCer or α-S-GalCer. The levels of IL-12 (A) and IL-10 (B) released into culture
supernatants were measured after 24 h by ELISA. Results are the means and SEM of 3 separate experiments. Square brackets indicate
which statistical comparisons are being made. *pb0.05; **pb0.01; ns, not significant.
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Figure 7 Intravenous administration of α-GalCer, but not α-
S-GalCer, to mice results in elevated serum IFN-γ and IL-4.
Serum levels of IFN-γ (left) and IL-4 (right) in mice after
intravenous treatment with PBS alone or PBS containing 1 μg or
2 μg α-GalCer or α-S-GalCer. Serum samples were harvested
3 h (top) or 18 h (bottom) after treatment. Data are from 3 to 6
mice per group and are representative of two separate
experiments. *pb0.05; **pb0.01 comparing effect of glycolipid
with PBS controls.
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glycolipids were present. These results indicate that iNKT
cells can partially induce DC maturation into cells with APC
phenotypes and that this maturation is augmented by
activating the iNKT cells with either α-S-GalCer or α-GalCer.
3.5. α-S-GalCer-stimulated iNKT cells induce IL-12,
and to a lesser degree, IL-10 release by
monocyte-derived DC
We also measured the amounts of IL-12 and IL-10 released
into supernatants by DC cultured alone or with LPS, α-GalCer
or α-S-GalCer or by co-cultures of DC with iNKT cells in the
absence or presence of α-GalCer or α-S-GalCer. Neither IL-12
nor IL-10 was released by DC cultured alone or with either
glycolipid, but LPS treatment induced the rapid release of
both IL-12 and IL-10 (Fig. 6). These cytokines were not
released by co-cultures of DC and unstimulated iNKT cells.
However, addition of α-GalCer or α-S-GalCer to DC-iNKT cell
co-cultures resulted in secretion of IL-12, with higher levels
that those induced by LPS. In contrast, co-cultures of DC and
iNKT cells with α-GalCer or α-S-GalCer released small
amounts of IL-10—significantly more than the amount
released by immature DC, but only slightly more than DC
matured with iNKT cells in the absence of glycolipid and less
than that induced by LPS-matured DC (Fig. 6). No cytokines
were released by DC co-cultured with PHA-stimulated PBMC,
as a non-iNKT cell control, in the absence or presence of
glycolipids. These data indicate that α-GalCer and α-S-
GalCer have similar immunostimulatory activities for DC, in
that they confer iNKT cells with the capacity to induce
potent IL-12 and moderate IL-10 secretion by DC.
3.6. Intravenous administration of α-GalCer, but
not α-S-GalCer, to mice resulted in elevated serum
IFN-γ and IL-4
Mice were injected intravenously with PBS-alone or PBS
containing 1 μg or 2 μg α-GalCer or α-S-GalCer and levels of
IFN-γ and IL-4 in serum were measured after 3 and 18 h by
ELISA. Figure 7 shows that α-GalCer, at either dose, induced
the secretion of significant amounts of both cytokines intoserum by 3 h that was sustained to 18 h. However, after
injection with α-S-GalCer, neither cytokine was detected at
elevated levels compared to mice given PBS alone. These
data suggest that, unlike α-GalCer, the thioglycoside
analogue does not activate murine iNKT cells in vivo.
4. Discussion
iNKT cells play central roles in innate and adaptive
immunity, being capable of killing cells [6], inducing
maturation of DC into antigen-presenting cells [9–12],
promoting differentiation of B cells into antibody-secreting
plasma cells [13,14] and releasing large quantities of Th1,
Th2, Th17 and regulatory T cell cytokines [7,8,37,38]. This
early immune stimulatory/regulatory role highlights the
potential importance of iNKT cells in infectious, immune-
mediated and metastatic disease and therapeutic activation
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in murine models [15–18]. Although deficiencies of iNKT cells
are found in humans with various diseases [19,20], clinical
trials for cancer involving α-GalCer stimulation of iNKT cells
have not yet demonstrated strong clinical efficacy [21,22].
One reason for this lack of clinical efficacy may be that iNKT
cells are found at ~100-fold lower frequencies in humans
compared to mice at most body locations tested [19,39].
Another may be that like in mice there are different NKT cell
subsets with different activities [17,23,24] and it is possible
that the “wrong” subsets were being used. A third possibility
is that murine and human iNKT cell subsets may respond
differently to α-GalCer and given the pleiotropy of iNKT cell
functions, it is likely that alternative glycolipid ligands may
alter iNKT cell responses and may therefore have superior
therapeutic value. In this regard, OCH, a synthetic analogue
of α-GalCer with a truncated acyl chain and a truncated
sphingoid base induces a predominant Th2 response in iNKT
cells and confers superior protection against experimental
autoimmune encephalomyelitis [28], collagen-induced ar-
thritis [40], diabetes [41]) and colitis [42]) in murine models.
Another α-GalCer analogue, α-GalCer C20:2, with a trun-
cated, unsaturated acyl chain was found to have an even
stronger protective effect against murine diabetes than OCH
[43]. In contrast, synthetic α-GalCer analogues containing
aromatic rings in their acyl or sphingosine tails, induced
polarized Th1 responses in iNKT cells and thereby conferred
superior protection against breast and lung cancers [33,44].
A C-glycoside analogue of α-GalCer (α-C-GalCer) also
induced enhanced Th1 responses through iNKT cells and
displayed 1000-fold more potent antimalarial activity and
100-fold greater antimetastatic activity [34].
In this report, we show that a thioglycoside analogue of
α-GalCer has stimulatory activity for human iNKT cells.
Thioglycosides, in which the glycosidic oxygen atom is
replaced with a sulphur atom, are tolerated by most
biological systems and are more resistant to enzymatic
cleavage and chemical degradation [45,46]. Thioglycosides
have more flexibility around the anomeric linkage com-
pared with the corresponding O-glycosides owing to the
longer C-S bond and weaker stereoelectronic effects. This
increased flexibility might cause α-S-GalCer to sit differ-
ently in the CD1d binding groove, resulting in an altered
structure of the glycolipid/CD1d complex and a change in
its avidity for the TCR of iNKT cells. Also, it is possible that
after binding with CD1d, the sugar head of α-S-GalCer may
orientate in a different angle from that of α-GalCer as C-S-C
bond angle is significantly smaller than the C-O-C angle,
which could result in differential recognition by TCR of iNKT
cells. We tested if α-S-GalCer can bind to CD1d and activate
iNKT cells and if it can induce altered responses of iNKT cells
compared to α-GalCer, which might translate into improved
clinical responses.
Our results show that α-S-GalCer stimulated human iNKT
cells in a CD1d-dependent manner and induced similar
patterns of cytokine secretion to those induced by the
prototype glycolipid α-GalCer. α-S-GalCer also primed CD1d-
positive target cells for lysis by iNKT cells. We also
investigated if α-S-GalCer could induce maturation of
monocyte-derived DC into APC, a key event in the initiation
of adaptive immune responses. We found that co-culturing
immature DC with iNKT cells in the absence of glycolipidantigen resulted in upregulation of CD54 and CD86 expres-
sion by the DC. Addition of either α-GalCer or α-S-GalCer
resulted in the additional upregulation of expression of
CCR7, CD40, CD83 and HLA-DR to levels comparable to those
induced by LPS and/or poly I:C. In contrast, iNKT cell-
mediated cytokine secretion by DC was dependent on the
presence of glycolipid antigen. iNKT cells but not non-iNKT
cells, in the presence of α-GalCer or α-S-GalCer induced the
release of large amounts of IL-12 and moderate amounts of
IL-10 by DC. Phenotypic maturation of DC in the absence of
IL-12 production (as occurred when DC were co-cultured with
iNKT cell alone) can lead to the development of tolerogenic
DC [47] and it is tempting to speculate that addition of
glycolipid to DC-iNKT cell co-cultures converts them from
tolerogenic (CD86+IL-12-) to immunogenic (CD86+IL-12+) DC.
While α-S-GalCer displayed stimulatory activity for
human iNKT cells in vitro, we were surprised to find
that this glycolipid did not activate murine iNKT cells in
vivo, as evidenced by the absence of elevated levels of
serum IFN-γ and IL-4. However, in the same mouse
experiments and as previously reported [31,34], the
prototype glycolipid α-GalCer induced rapid secretion of
both cytokines into serum. Blauvelt and co-workers [48] also
reported no bioactivity of α-S-GalCer in mice. Our finding
indicates that murine iNKT cells respond to α-S-GalCer in vivo
differentially from human iNKT cells in vitro. Whether
α-S-GalCer stimulates murine iNKT cells in vitro and human
iNKT cells in vivo remains to be tested. This difference
between antigen recognition by murine and human iNKT cells
highlights the importance of testing such therapeutic ligands
with human cells.
Our results clearly show that α-S-GalCer exhibits
bioactivity by stimulating CD1d-dependent cytotoxic, cyto-
kine and adjuvant activities of iNKT cells similar to those
activated by α-GalCer. Two other groups have synthesized
similar α-S-GalCer-type analogues but were unable to
demonstrate recognition of this compound by iNKT cells.
Chang and co-workers [33] synthesized and tested a number
of α-GalCer analogues and found that an α-S-GalCer form
presented by monocytes which were co-cultured with
human iNKT cells failed to stimulate IFN-γ, IL-2, IL-6, IL-
10 or IL-12 release. This compound did induce weak IL-4
production but significantly lower amounts than those
induced by α-GalCer. Furthermore, α-S-GalCer did not
induce human iNKT cell proliferation, nor did it prolong
survival of mice bearing lung or breast tumors, as occurred
when α-GalCer was used. In another study, Blauvelt and co-
workers [48] administered an α-S-GalCer to non-obese
diabetic and C56B1/6 mice but, in accordance with our
study, failed to demonstrate expansion of or intracellular
cytokine expression by iNKT cells, or proliferation or
cytokine production by splenocytes from these mice after
restimulation with α-S-GalCer. We are unable to say why
our α-S-GalCer showed bioactivity for human iNKT cells
while bioactivity was not found in a previous study [33], but
it may reflect the novel procedure used in our study for
α-S-GalCer synthesis. In our procedure, an α-galactosyl thiol
was prepared from a benzylated 1,6-anhydrogalactose and
coupled it with an electrophilic sphingoid iodide under phase
transfer conditions [36]. This method yielded S-GalCer
exclusively as α-anomers, whereas in the study by Blauvelt
and co-workers [48], the construction of thioglycosidic bond
205Human invariant natural killer T cells with a thioglycoside analoguewas non-stereoselective, and α-S-GalCer had to be isolated
from the mixture of α- and β-galactosyl thiols after the
coupling reaction. It is possible that low-levels of the β-
enantiomer inhibited the effects of the α-form.
In conclusion, we have shown that synthetic α-S-GalCer
can stimulate the effector, regulatory and adjuvant activi-
ties of human iNKT cells. It is not superior to its parent
compound α-GalCer in that it induces the release of the same
cytokines with similar potency, it is a similar or less potent
stimulator of antitumor cytotoxicity by iNKT cells, and it
comparably induces maturation and cytokine secretion by
dendritic cells in the presence of iNKT cells. Therefore, α-S-
GalCer is unlikely to replace α-GalCer as a therapeutic
agent. However, α-S-GalCer may be superior to α-GalCer as a
parent compound for developing therapeutic analogues with
shorter acyl chains, more double bonds and/or added
aromatic groups, as have been introduced to α-GalCer and
shown to alter iNKT cell stimulatory capacity [28–35] and
therapeutic efficacy in mice [28,34,40–44]. Thioglycosides
are easier to prepare than O-linked glycosides, since sulphur
is much more nucleophilic than oxygen, allowing easier
formation of the C-S bond. This has enabled several
strategies for the synthesis of S-linked glycoconjugates to
be developed [36,46,49]. Thioglycosides also display in-
creased solubility and stability in biological systems [50–53].
S-linked glycoconjugates display lower susceptibility to
chemical and enzymatic hydrolysis with the rate of hydrolysis
of the thioglycosidic bond by glycohydrolases being several
orders of magnitude lower that that of the corresponding O-
linked glycosides [49]. Furthermore, glycoconjugates with at
least one glycosidic oxygen atom replaced with a sulphur
atom can act as competitive inhibitors of various glycoside
hydrolases [54]. Our demonstration of the bioactivity of α-S-
GalCer together its ease of synthesis, flexibility for making
analogues and stability in biological systems, places thiogly-
coside analogues of α-GalCer as potentially superior immune
stimulants for human use.
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